Cellanyx, LLC is a growth stage biotech company based in Beverly, MA that specializes in developing innovative biomarker tests for solid tumors. Their proprietary technology combines machine vision and AI-driven analysis of live single tumor cells to improve risk stratification and enhance shared clinical decision-making for various types of cancers, including prostate, breast, kidney, bladder, and lung cancers.
With a focus on phenotypic appearance and dynamics, Cellanyx's tests provide clinicians with valuable insights into tumor aggressiveness, enabling them to make more informed treatment plans and improve patient outcomes. By leveraging their clinically-proven, patented, and scalable technology, Cellanyx aims to reduce unnecessary treatment costs associated with low-to-intermediate grade tumors, benefiting both patients and third-party payors. Investors are drawn to Cellanyx's first-in-class approach, which offers a unique and actionable solution for cancer risk stratification.
Generated from the website